All filters
Abstracts
A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV
V. Bukkems Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets
R. Singh Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age
M. Nikanjam Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Mechanistic Modelling for the Quantitative Evaluation of ARV Penetration in Lymphatic Tissues
F. Bunglawala Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
TFVdp/FTCtp Concentrations in Rectal Samples: No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ Cells
M Cottrell Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Intracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study Design
M. Cottrell Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure
M. Ferrara Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel (LNG)
S. Joshi Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Dolutegravir
T. Pene Dumitrescu  Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Antiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and Rilpivirine
P. Patel Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Fostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 Infection
K. Moore Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants
T. Pene Dumitrescu Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of Jnj-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers
M. Pastagia Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV)
T. Kakuda Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Acceptability and concerns over the use of PrEP in Puerto Rico
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Abstracts
Protein binding determination of second-line anti-tuberculosis drugs in vitro using an ultrafiltration technique
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Comparison of a Bayesian forecasting algorithm handling inter-occasion variability and a linear regression approach for dose individualization of rifampicin
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Mathematical modeling using in vitro checkerboard assay data: Clofazimine as a potentially synergistic anti-TB drug
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Levofloxacin urine kinetics and development of a colorimetric assay for therapeutic drug monitoring among people living with HIV and TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Optimal dose individualisation of rifampicin needs to account for between-occasion variability
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Mechanistic modelling of time-to-positivity and colony-forming unit in tuberculosis patients on high-dose rifampicin to improve understanding of biomarker relation
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019